Supported in part by National Institutes of Health/National Eye Institute (Bethesda, MD) Grants EY021818 and EY025056 (FAM), and Core Grant P30EY022589; an unrestricted grant from Research to Prevent Blindness; fellowships from Brazilian National Council for Scientific and Technological Development (CNPq) 233829/2014-8 (ADF); fellowships from National Health and Medical Research Council (NHMRC) 1104985 (ZW). The authors alone are responsible for the content and writing of this paper. The study was registered at ClinicalTrials.gov with registration number NCT00221897.
Disclosure: A. Diniz-Filho, None; E.R. Boer, None; A. Elhosseiny, None; Z. Wu, None; M. Nakanishi, None; F.A. Medeiros, Alcon Laboratories (F), Bausch & Lomb (F), Carl Zeiss Meditec (F), Heidelberg Engineering (F), Merck (F), Allergan (F), Sensimed (F), Topcon (F), Reichert (F), National Eye Institute (F), Allergan (C), Carl Zeiss Meditec (C), Novartis (C)